Halozyme Therapeutics Aktie
65,84
EUR
+1,06
EUR
+1,64
%
76,94
USD
-2,57
USD
-3,23
%
Werbung
Halozyme Therapeutics Aktie Analyse
| 15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. | |
| 27.09.12 | Halozyme Therapeutics neutral | UBS AG | |
| 12.08.08 | Halozyme Therapeutics hold | Brean Murray, Carret & Co., LLC |
Werbung
Werbung